La cadena de opciones muestra datos clave de las opciones de acciones de Bioage Labs a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Bioage Labs..

Bioage Labs (NASDAQ:BIOA) Bolsa, Cadena de Opciones

Bioage Labs

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.

Bioage Labs Inc

BIOASIS TECHNOLOGIES INC by Bioasis Technologies Inc.

Bioasis Technologies Inc

BioAdaptives Inc

BioArctic AB

BioAtla Inc

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies Inc

WIIM

BIOA

BioAge Labs shares are trading higher after the company announced a multi-year collaboration with Novartis to discover novel targets for therapies addressing age-related diseases.

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging
Novartis to pay up to $20M comprising upfront payments and research funding; BioAge may receive up to $530M in future long-term research, development, and commercial milestones
RICHMOND, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced a multi-year research collaboration with Novartis. The collaboration aims to identify and validate multiple novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate the beneficial effects of physical exercise.

Biotech

News

Contracts

General

BioAge Labs Announces Multi-Year Collaboration With Novartis To Discover Novel Targets For Therapies That Address Age-Related Diseases And Conditions; Novartis To Pay Up To $20M Comprising Upfront Payments And Research Funding; BioAge May Receive Up To $530M In Future Long-Term Research, Development, And Commercial Milestones

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock rose 110.0% to $4.41 during Monday's pre-market session. The company's market cap stands at $3.6 million. </li>
<li>Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) stock rose 34.05% to $2.48. The market value of their outstanding shares is at $92.8 million. </li>
<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) shares increased by 25.17% to $1.84. The company's market cap stands at $148.9 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) shares increased by 20.82% to $14.39. The company's market cap stands at $118.7 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares moved upwards by 16.71% to $3.77. The market value of their outstanding shares is at $15.9 million. </li>
<li>Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) shares increased by 14.22% to $8.94. The company's market cap stands at $470.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) stock decreased by 72.1% to $5.6 during Monday's pre-market session. The company's market cap stands at $200.7 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 51.33% to $1.65. The company's market cap stands at $2.6 million. </li>
<li>Radiopharm Theranostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) shares fell 40.22% to $11.3. The company's market cap stands at $24.5 billion. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares decreased by 20.69% to $3.03. The company's market cap stands at $317.8 million. </li>
<li>Invizyne Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZTC#NASDAQ">IZTC</a>) shares fell 18.36% to $10.81. The market value of their outstanding shares is at $103.0 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 16.46% to $1.98. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CRVO

IPHA

IZTC

RADX

RVNC

SONN

STRM

12 Health Care Stocks Moving In Monday's Pre-Market Session

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday.
The Dow traded down 0.24% to 44,533.63 while the NASDAQ fell 0.44% to 19,772.99. The S&amp;P 500 also fell, dropping, 0.45% to 6,063.09.
Check This Out: <a href="https://www.benzinga.com/24/12/42391708/tesla-to-370-here-are-10-top-analyst-forecasts-for-monday">Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday</a>
Leading and Lagging Sectors Energy shares jumped by 0.5% on Monday.
In trading on Monday, communication services shares fell by 1.2%.
Top Headline
U.S. wholesale inventories increased by 0.2% month-over-month to $905 billion in October, in- line with the preliminary reading and compared to a 0.2% decline in the previous month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>LeddarTech Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) shares shot up 308% to $1.27 after the company announced a collaboration with Texas Instruments for advanced driver assistance systems and autonomous driving solutions.</li>
<li>Shares of Fangdd Network Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) got a boost, surging 58% to $0.9169. Shares of US-listed Chinese stocks traded higher following reports suggesting Chinese officials would embrace a &#8216;moderately loose&#8217; monetary policy.</li>
<li>Pactiv Evergreen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTVE#NASDAQ">PTVE</a>) shares were also up, gaining 19% to $17.42 after the company announced it will merge with Novolex in which Pactiv shareholders will receive $18.00 per share in cash.</li>
</ul>
Equities Trading DOWN
<ul>
<li>BioAge Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) shares dropped 76% to $4.88 as the company announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate, azelaprag.</li>
<li>Shares of Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) were down 58% to $1.4401 after the company announced a definitive agreement with investors for the purchase and sale of 18.75 million ordinary shares, expecting gross proceeds of $15 million.</li>
<li>Riot Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) was down, falling 11% to $11.53 after the company announced a $500 million offering of convertible senior notes.</li>
</ul>
Commodities In commodity news, oil traded up 2% to $68.57 while gold traded up 1% at $2,686.30.
Silver traded up 3.4% to $32.645 on Monday, while copper rose 1.8% to $4.2725.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 gained 0.14%, Germany's DAX fell 0.19% and France's CAC 40 rose 0.72%. Spain's IBEX 35 Index fell 0.50%, while London's FTSE 100 rose 0.52%.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index gaining 2.76%, China's Shanghai Composite Index falling 0.05% and India's BSE Sensex falling 0.25%.
Economics
U.S. wholesale inventories increased by 0.2% month-over-month to $905 billion in October, in- line with the preliminary reading and compared to a 0.2% decline in the previous month.&nbsp;&nbsp;&nbsp;&nbsp;
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42390276/this-analyst-with-86-accuracy-rate-sees-around-21-upside-in-chewy-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 86% Accuracy Rate Sees Around 21% Upside In Chewy &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

LDTC

PTVE

RIOT

Crude Oil Gains 2%; BioAge Labs Shares Plunge

U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 100 points on Monday.
Following the market opening Monday, the Dow traded down 0.18% to 44,562.45 while the NASDAQ fell 0.68% to 19,724.61. The S&amp;P 500 also fell, dropping, 0.51% to 6,059.08.
Check This Out: <a href="https://www.benzinga.com/24/12/42391708/tesla-to-370-here-are-10-top-analyst-forecasts-for-monday">Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday</a>
Leading and Lagging Sectors Energy shares jumped by 1.2% on Monday.
In trading on Monday, communication services shares fell by 1.4%.
Top Headline
U.S. wholesale inventories increased by 0.2% month-over-month to $905 billion in October, in- line with the preliminary reading and compared to a 0.2% decline in the previous month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>LeddarTech Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) shares shot up 336% to $1.3280 after the company announced a collaboration with Texas Instruments for advanced driver assistance systems and autonomous driving solutions.</li>
<li>Shares of Fangdd Network Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) got a boost, surging 126% to $1.3050. Shares of US-listed Chinese stocks traded higher following reports suggesting Chinese officials would embrace a &#8216;moderately loose&#8217; monetary policy.</li>
<li>Asset Entities Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) shares were also up, gaining 83% to $0.8402.</li>
</ul>
Equities Trading DOWN
<ul>
<li>BioAge Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) shares dropped 76% to $4.8350 as the company announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate, azelaprag.</li>
<li>Shares of Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) were down 57% to $1.4501 after the company announced a definitive agreement with investors for the purchase and sale of 18.75 million ordinary shares, expecting gross proceeds of $15 million.</li>
<li>Radiopharm Theranostics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) was down, falling 45% to $10.50.</li>
</ul>
Commodities In commodity news, oil traded up 2.1% to $68.64 while gold traded up 1.2% at $2,692.00.
Silver traded up 3.6% to $32.735 on Monday, while copper rose 2.1% to $4.2825.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 gained 0.2%, Germany's DAX fell 0.1% and France's CAC 40 rose 0.8%. Spain's IBEX 35 Index fell 0.5%, while London's FTSE 100 rose 0.5%.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index gaining 2.76%, China's Shanghai Composite Index falling 0.05% and India's BSE Sensex falling 0.25%.
Economics
U.S. wholesale inventories increased by 0.2% month-over-month to $905 billion in October, in- line with the preliminary reading and compared to a 0.2% decline in the previous month.&nbsp;&nbsp;&nbsp;&nbsp;
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42390276/this-analyst-with-86-accuracy-rate-sees-around-21-upside-in-chewy-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 86% Accuracy Rate Sees Around 21% Upside In Chewy &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

ASST

Nasdaq Down Over 100 Points; US Wholesale Inventories Rise By 0.2%

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Loop Capital raised the price target for Maplebear Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) from $49 to $56. Loop Capital analyst Rob Sanderson maintained a Buy rating. Maplebear shares closed at $44.19 on Friday. <a href="https://www.benzinga.com/quote/CART/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays boosted the price target for Intercontinental Exchange, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>) from $173 to $187. Barclays analyst Benjamin Budish maintained an Overweight rating. Intercontinental Exchange shares closed at $155.93 on Friday. <a href="https://www.benzinga.com/quote/ICE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo boosted Hess Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) price target from $151 to $193. Wells Fargo analyst Roger Read upgraded the stock from Equal-Weight to Overweight. Hess shares settled at $141.53 on Friday. <a href="https://www.benzinga.com/quote/HES/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley increased The Bank of New York Mellon Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) price target from $82 to $94. Morgan Stanley analyst Betsy Graseck upgraded the stock from Equal-Weight to Overweight. Bank of New York Mellon shares closed at $80.51 on Friday. <a href="https://www.benzinga.com/quote/BK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup slashed BioAge Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) price target from $45 to $7. Citigroup analyst Samantha Semenkow downgraded the stock from Buy to Neutral. BioAge Labs shares closed at $20.09 on Friday.  <a href="https://www.benzinga.com/quote/BIOA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group boosted RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) price target from $290 to $330. Telsey Advisory Group analyst Cristina Fernandez maintained a Market Perform rating on the stock. RH shares closed at $376.07 on Friday. See how other analysts view this stock.</li>
<li>Baird raised the price target for VeriSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>) from $200 to $250. Baird analyst Robert Oliver upgraded the stock from Neutral to Outperform. VeriSign shares settled at $191.14 on Friday. <a href="https://www.benzinga.com/quote/VRSN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham boosted Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) price target from $300 to $330. Needham analyst Chris Pierce maintained a Buy rating. Carvana shares closed at $251.21 on Friday. <a href="https://www.benzinga.com/quote/CVNA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Ascendiant Capital cut the price target for Lucid Diagnostics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) from $7.25 to $7. Ascendiant Capital analyst Edward Woo maintained a Buy rating. Lucid Diagnostics shares closed at $0.8401 on Friday. <a href="https://www.benzinga.com/quote/LUCD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank raised Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) price target from $295 to $370. Deutsche Bank analyst Edison Yu maintained a Buy rating. Tesla shares closed at $389.22 on Friday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="467" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09100302/image-65-1024x467.png" alt="" class="wp-image-683364" style="width:639px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09100302/image-65-1024x467.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09100302/image-65-300x137.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09100302/image-65-768x350.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09100302/image-65.png 1220w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42380712/how-to-earn-500-a-month-from-oracle-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Oracle Stock Ahead Of Q2 Earnings</a></li>
</ul>

Price Target

Analyst Ratings

CART

CVNA

LUCD

TSLA

VRSN

Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Monday.
Shares of BioAge Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) fell sharply in today's pre-market trading after the company announced discontinuation of STRIDES Phase 2 clinical trial evaluating Azelaprag in combination with Tirzepatide <a href="https://www.benzinga.com/quote/BIOA/news">for the treatment of obesity.</a>
BioAge Labs shares tumbled 68.6% to $6.30 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Palmer Square Capital BDC Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSBD#NASDAQ">PSBD</a>) shares tumbled 18.3% to $13.00 in pre-market trading.</li>
<li>Bicara Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) fell 14.7% to $18.00 in pre-market trading after gaining 8% on Friday.</li>
<li>ZJK Industrial Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) fell 10.9% to $12.55 in pre-market trading.</li>
<li>Heritage Commerce Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTBK#NASDAQ">HTBK</a>) declined 9.7% to $9.50 in pre-market trading.</li>
<li>Bel Fuse Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFB#NASDAQ">BELFB</a>) declined 7.1% to $78.00 in pre-market trading.</li>
<li>Riot Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) fell 6.7% to $12.08 in pre-market trading. Riot Platforms announced a proposed private offering of $500 million of convertible senior notes.</li>
<li>ZimVie Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) fell 6.5% to $13.03 in pre-market trading.</li>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) declined 5.8% to $378.00 in pre-market trading after gaining around 6% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42380712/how-to-earn-500-a-month-from-oracle-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Oracle Stock Ahead Of Q2 Earnings</a></li>
</ul>

Pre-Market Outlook

BCAX

BELFB

HTBK

PSBD

ZIMV

BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session

BioAdge Labs shares are trading lower after Jefferies downgraded the stock from Buy to Hold and Citigroup downgraded the stock from Buy to Neutral. Additionally, both firms cut their price target on the stock to $7.

On Friday, BioAge Labs&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42374184/bioage-labs-announces-discontinuation-of-strides-phase-2-clinical-trial-evaluating-azelaprag-in-co" rel="noreferrer noopener">drug candidate, azelaprag</a>.
STRIDES was being conducted in collaboration with Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Chorus clinical development organization. Top-line results were anticipated in the third quarter of 2025.
The move follows after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag.
STRIDES is a Phase 2 clinical trial of azelaprag as monotherapy and in combination with tirzepatide that planned to enroll approximately 220 individuals with obesity aged 55 years and older.
Tirzepatide is an active ingredient of Eli Lilly&#8217;s popular Zepbound and Mounjaro.
The trial was designed to evaluate the efficacy as measured by body weight reduction and other outcomes, safety, and tolerability of two oral doses of azelaprag (300 mg, once or twice daily) in combination with tirzepatide (5 mg subcutaneous injection once weekly).
An azelaprag monotherapy arm was included to provide additional safety information.
The company said no transaminase elevations were observed in the tirzepatide only treatment group.
Of 204 subjects enrolled in STRIDES, 11 subjects in the azelaprag treatment groups were observed to have transaminase (liver enzymes) elevations with no clinically significant symptoms. Dosing of all subjects will be discontinued, and no additional subjects will be enrolled.
Clinical follow-up of enrolled subjects will continue off-drug. The company intends to further analyze available STRIDES clinical data from all enrolled subjects and share updated plans for azelaprag in the first quarter of 2025.
The company&#8217;s brain-penetrant NLRP3 inhibitors are progressing toward IND submission, anticipated in the second half of 2025. The NLRP3 inhibitor program targets neuroinflammation linked to metabolic and neurodegenerative diseases.
As of September 30, BioAge had approximately $334.5 million in cash and cash equivalents, which is expected to be sufficient to fund operations and capital <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41825231/bioage-labs-reports-third-quarter-2024-financial-results-and-provides-business-updates" rel="noreferrer noopener">expenses into 2029</a>.
In October, BioAge Labs closed its upsized initial public offering of 12.65 million shares at <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41129276/bioage-labs-announces-closing-of-initial-public-offering-full-exercise-of-underwriters-option-to-p" rel="noreferrer noopener">$18 per share</a>.
Price Action: BIOA stock is down 70% at $6.03 during the premarket session at last check Monday.
Photo via Shutterstock.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42372905/lululemons-strong-earnings-and-share-buyback-push-analysts-to-increase-price-targets-details-here" target="_blank" rel="noreferrer noopener">Lululemon&#8217;s Strong Earnings and Share Buyback Push Analysts to Increase Price Forecast</a></li>
</ul>

Health Care

Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns

Citigroup analyst Samantha Semenkow downgrades Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) from Buy to Neutral and lowers the price target from $45 to $7.

Downgrades

Citigroup Downgrades Bioage Labs to Neutral, Lowers Price Target to $7

Jefferies analyst Roger Song downgrades Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) from Buy to Hold and lowers the price target from $42 to $7.

Jefferies Downgrades Bioage Labs to Hold, Lowers Price Target to $7

Shares of The Interpublic Group of Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>) rose sharply in <a href="https://www.benzinga.com/quote/IPG">today's pre-market</a>.
The Wall Street Journal reported Sunday that Omnicom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>) is in advanced talks to merge with Interpublic.
Interpublic shares jumped 13.8% to $33.32 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Zeo Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) gained 106.6% to $2.79 in pre-market trading.</li>
<li>MEDIROM Healthcare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) rose 74.1% to $4.98 in pre-market trading. M3 Group joined MEDIROM Mother Labs&#8217; Series A financing round at JPY9 billion (as of Dec. 1, approximately USD $59,000,000) pre-money valuation.</li>
<li>China SXT Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) gained 73.4% to $0.6490 in pre-market trading.</li>
<li>Gaxos.ai Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GXAI#NASDAQ">GXAI</a>) gained 58.1% to $4.11 in pre-market trading. Gaxos.ai shares jumped 83% on Friday ater the company announced the release of its visual editor for AI solutions for game developers and publishers..</li>
<li>Fangdd Network Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) gained 51.4% to $0.8753 in pre-market trading after rising over 5% on Friday.</li>
<li>Algorhythm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) rose 27.2% to $0.1170 in pre-market trading. Algorhythm Holdings announced the closing of $9.5 million public offering.</li>
<li>Satellogic Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATL#NASDAQ">SATL</a>) gained 25% to $4.90 in pre-market trading after jumping 25% on Friday.</li>
<li>ESSA Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESSA#NASDAQ">ESSA</a>) climbed 17.7% to $24.00 in pre-market trading.</li>
<li>Rent the Runway, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>) gained 17% to $15.00 in pre-market trading after jumping 14% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>BioAge Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) shares tumbled 68.6% to $6.30 in pre-market trading after the company announced discontinuation of STRIDES Phase 2 clinical trial evaluating Azelaprag in combination with Tirzepatide for the treatment of obesity.</li>
<li>Golden Minerals Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AUMN#NYSE">AUMN</a>) declined 25.7% to $0.2000 in pre-market trading. Golden Minerals announced NYSE American notice to commence delisting.</li>
<li>Healthcare Triangle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 19.4% to $0.95 in pre-market trading after jumping over 70% on Friday.</li>
<li>The Lion Electric Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEV#NYSE">LEV</a>) fell 14.5% to $0.3079 in pre-market trading after gaining around 8% on Friday.</li>
<li>Oriental Rise Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIS#NASDAQ">ORIS</a>) fell 13.4% to $3.14 in pre-market trading after dipping 94% on Friday.</li>
<li>Zhibao Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAO#NASDAQ">ZBAO</a>) shares fell 12.4% to $2.44 in pre-market trading after gaining 16% on Friday.</li>
<li>SuperCom Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCB#NASDAQ">SPCB</a>) dipped 12.4% to $2.89 in pre-market trading after jumping 5% on Friday.</li>
<li>Sharplink Gaming Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) fell 12.2% to $0.82 in pre-market trading after jumping 79% on Friday.</li>
<li>Avalon Globocare Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALBT#NASDAQ">ALBT</a>) shares dipped 12.1% to $3.62 in pre-market trading after jumping 55% on Friday.</li>
<li>Color Star Technology Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) fell 11.1% to $3.03 in today's pre-market trading after dipping 12% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42380712/how-to-earn-500-a-month-from-oracle-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Oracle Stock Ahead Of Q2 Earnings</a></li>
</ul>

ALBT

AUMN

ESSA

GXAI

HCTI

ORIS

RENT

RIME

SATL

SBET

SPCB

SXTC

ZBAO

Why Interpublic Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Trading Halt: Halt status updated at 4:55:00 PM ET: Quotation Resumption: News and Resumption Times

Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag
Company will evaluate data from patients enrolled to date and share updated plans for azelaprag in Q1 2025
In parallel to evaluating azelaprag, Company will continue to advance earlier platform-derived programs, including IND submission for CNS penetrant NLRP3 inhibitor anticipated in the second half of 2025
RICHMOND, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company has made the decision to discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag as monotherapy and in combination with tirzepatide after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag. No transaminase elevations were observed in the tirzepatide only treatment group.

BioAge Labs Discontinues STRIDES Phase 2 Trial Of Azelaprag For Obesity Following Liver Transaminitis Observations; Plans To Evaluate Data And Provide Updates On Azelaprag In Q1 2025 While Advancing NLRP3 Inhibitor Program With IND Submission Expected In Late 2025

Trading Halt: Halted at 4:00:10 p.m. ET - Trading Halt: Halt News Pending

BioAge Labs shares are trading higher after the company announced it will present new preclinical data for its lead product candidate Azelapragor at ObesityWeek 2024.

Events

BioAge Labs To Present New Preclinical Data For Lead Product Candidate Azelapragor At ObesityWeek 2024

CORRECTION: Bioage Labs Ticker Is "BIOA"

BioAge Labs shares are trading higher after multiple firms initiated coverage on the stock with Buy ratings.

Citigroup analyst Samantha Semenkow initiates coverage on Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) with a Buy rating and announces Price Target of $45.

Initiation

Citigroup Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $45

17:00 EST BIOAGE Labs (BIOA) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ne...

BIOAGE Labs Inc trading resumes

BioAge stock craters 75% on obesity drug study halt (update)

BioAge stock craters 70% on obesity drug study halt (update)

Biggest stock movers Monday: SMCI, MOMO, and more

Jefferies downgraded BioAge Labs (BIOA) to Hold from Buy with a price target of $7, down from $42. The company discontinued the Phase 2 obesity stu...

BioAge Labs downgraded to Hold from Buy at Jefferies

Citi downgraded BioAge Labs (BIOA) to Neutral from Buy with a price target of $7, down from $45, after the company disclosed an elevated liver enzy...

BioAge Labs downgraded to Neutral from Buy at Citi

Biggest stock movers Monday: PLTR, SMCI, MOMO, and more

Morgan Stanley downgraded BioAge Labs (BIOA) to Underweight from Overweight with a price target of $5, down from $40. The company discontinued its ...

BioAge Labs downgraded to Underweight from Overweight at Morgan Stanley

BioAge Labs (BIOA) announced a multi-year research collaboration with Novartis (NVS). The collaboration aims to identify and validate multiple nove...

BioAge Labs announces multi-year collaboration with Novartis

BioAge, Novartis team up to discover age-related disease targets

AFMD

AMGN

MOMO

PLTR

RDDT

SMCI

Press Releases

BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures – Hagens Berman

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioAge Labs, Inc. - BIOA

Legal

BIOA INVESTOR LAWSUIT: BioAge Labs Investors with Losses are Notified of Continuing Investigation into the Company – Contact BFA Law (NASDAQ:BIOA)

BIOA INVESTOR REMINDER: Investors with Losses on BioAge Labs are Encouraged to Contact BFA Law about its Ongoing Investigation (NASDAQ:BIOA)

BIOA STOCK UPDATE: BioAge Labs, Inc. Investors are Notified of Ongoing Investigation into the Company; Contact BFA Law (NASDAQ:BIOA)

BioAge Labs Investigation: Investors are Alerted the Company is Being Investigated after Phase 2 Trial Results – Contact BFA Law if You Lost Money (NASDAQ:BIOA)

BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman

BIOA INVESTIGATION ALERT: BFA Law Alerts BioAge Labs, Inc. Investors of Ongoing Investigation – Contact the Firm if You Lost Money (NASDAQ:BIOA)

Short Sellers

Bragar Eagel & Squire, P.C. Is Investigating Franklin, MediaAlpha, e.l.f. Beauty, and BioAge and Encourages Investors to Contact the Firm

Comments

Bioage Labs

Bioage Labs (BIOA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL